Amylyx Says Phase 3 Trial of Avexitide For Post-Bariatric Hypoglycemia Met Main Goal

Aug. 18 (Reuters) - Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX):

• Amylyx Pharmaceuticals announced positive topline results from its Phase 3 Lucidity clinical trial of avexitide in post-bariatric hypoglycemia.
• Amylyx Pharmaceuticals said Lucidity met the FDA-agreed-upon primary endpoint and all secondary endpoints.
• Amylyx Pharmaceuticals said avexitide was well-tolerated with a favorable safety profile.
• Amylyx said it plans to submit an NDA for avexitide with the FDA by year-end and plans for a potential launch in 2027, if approved.